focus -WSS

focus

author：comprehensive 2025-10-01 17:35:02 - browse：447

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

WSS

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Popular nasal decongestant doesn't actually relieve congestion

WATCH: Why do bright lights make us see spots?

Pregnancy discrimination could be enabled by AI

The woman behind the Dana Farber

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

Private equity could exacerbate cardiology's overuse problem, experts fear

Dobbs anniversary: the lost opportunity of abortion as health care

Walmart eyes Medicare Advantage provider ChenMed

At least 13 dead in Texas as scorching temps continue

Diverse clinical trials: Why aren’t we there yet?

Hollywood unions extend contract negotiations for actors

Pregnancy discrimination could be enabled by AI

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA approves updated Covid vaccines

knowledge

CMS should re

FDA needs staff influx to meet gene therapy needs, Marks says

After sickle

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Will the IRA bring competition to the biologics market?

Will the IRA bring competition to the biologics market?

leisure time

focus

Wikipedia

knowledge